JPRN-jRCT1031210111
Recruiting
Phase 4
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults - Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults
FUKUSHIMA SHINJI0 sites20 target enrollmentMay 25, 2021
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Prevention of Yellow fever, Measles and Rubella
- Sponsor
- FUKUSHIMA SHINJI
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Japanese healthy adults who need MR and yellow fever vaccines
- •2\) 20 years old and over and under 60 years old
- •3\) No history of yellow fever
- •4\) No history of immunization of yellow fever vaccine
Exclusion Criteria
- •1\) Manifest fever (37\.5 or more temperature)
- •2\) Suffering from severe acute illness
- •3\) History of anaphylaxis
- •4\) Immunodeficiency
- •5\) HIV infection
- •6\) Immunosuppressive and Immunomodulatory Therapies
- •7\) Neurological disorder
- •8\) Thymus Disorder
- •9\) History of hypersensitivity to MR and yellow fever vaccine
- •10\) Other chronic medical conditions
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adultsYellow fever, Measles and RubellaJPRN-UMIN000042738Tokyo Medical University Hospital Travellers' Medical Center14
Active, not recruiting
Phase 1
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-004118-12-ATMedical University of Vienna256
Not yet recruiting
Not Applicable
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in MozambiquePoliovirusPACTR202404654347323World Health Organization888
Active, not recruiting
Not Applicable
An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and 12 months of age, and a booster dose at 5½ years of age. - Tdap Booster studyEUCTR2008-008195-13-SESwedish Institute for Infectious Disease Control (SMI)
Completed
Not Applicable
Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaJPRN-UMIN000014703The University of Tokyo Hospital15